iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of cancer, today announced the installation of two veterinary Xoft Axxent
eBx™ electronic brachytherapy systems at veterinary clinics in Rhode Island and New York. The two systems were recently placed as the result of an exclusive agreement established last year with Sound-Eklin™, a division of VCA Antech and the worldwide leader in veterinary imaging.
“Electronic Brachytherapy has proven valuable for the treatment of breast, skin and endometrial cancers. This strategic partnership with Sound-Eklin not only allows us to make improvements to the world of veterinary oncology, but also continues our mission of finding new ways to leverage this platform technology to benefit additional markets,” said Ken Ferry, President and CEO of iCAD.
Typically, radiation therapy for cancer treatment in animals involves external radiation therapy, a beam of high-energy X-rays delivered externally to the location of the tumor. External beam therapy is delivered in dozens of fractions, requiring a pet owner to commit to a treatment plan that can be both burdensome and costly. The Axxent System uses a proprietary isotope-free miniaturized X-ray source to deliver radiation in minimally shielded environments directly to the cancerous tumor bed – enabling the treatment of smaller tumors, reducing radiation exposure to healthy tissue and allowing radiation therapy to be completed in fewer sessions.
“In veterinary oncology, the goal is always to deliver appropriate and effective care to animals, while being sensitive to the needs of the pet owner,” Greg Stoutenburgh, VP of Marketing for Sound
Eklin. “The Axxent System and electronic brachytherapy enables veterinarians to provide new hope to their patients and clients - by delivering radiation in a targeted way, so they can minimize harmful radiation exposure to healthy tissue while making radiation therapy more feasible and accessible for pet owners.”
Designed for the delivery of radiation oncology in medical and veterinary practices, the Axxent System is cleared by the U.S. Food & Drug Administration (FDA) for the treatment of early stage breast cancer, skin cancer and endometrial cancer. The system is also cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated including Intraoperative Radiation Therapy (IORT). As a platform technology, the Axxent System is designed to deliver non-radioactive therapy directly to cancer sites with minimal radiation exposure to surrounding healthy tissue.